Generic Medicine Info
Indications and Dosage
Type 2 diabetes mellitus
Adult: As monotherapy or in combination with other antidiabetic agents: 25 mg once daily.
Renal Impairment
CrCl (mL/min) Dosage
15-<30 6.25 mg once daily.
30-<60 12.5 mg once daily.
May be taken with or without food.
Type 1 diabetes mellitus or diabetic ketoacidosis.
Special Precautions
Patient with abnormal LFT, history of pancreatitis, moderate to severe heart failure. Hepatic and moderate to severe renal impairment. Pregnancy and lactation. Not intended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Adverse Reactions
Significant: Severe arthralgia, bullous pemphigoid, acute pancreatitis, macrovascular outcomes, heart failure.
Gastrointestinal disorders: GERD, abdominal pain, constipation.
Nervous system disorders: Headache.
Renal and urinary disorders: Decreased estimated GFR, renal function abnormality. Renal disease, renal impairment.
Respiratory, thoracic and mediastinal disorders: Upper respiratory infection, nasopharyngitis.
Skin and subcutaneous tissue disorders: Pruritus, rash.
Potentially Fatal: Hepatic failure. Rarely, hypersensitivity reactions (e.g. anaphylaxis, angioedema, Steven-Johnson syndrome, erythema multiforme).
Monitoring Parameters
Monitor serum glucose, glycosylated Hb (HbA1c); LFT at baseline; renal function prior to initiation of therapy and periodically thereafter; signs and symptoms of pancreatitis, hepatic and heart failure, hypersensitivity.
Drug Interactions
Increased risk of hypoglycaemia with sulfonylurea (e.g. metformin), thiazolidinedione (e.g. pioglitazone) and insulin.
Description: Alogliptin inhibits dipeptidylpeptidase-4 (DPP-4), an enzyme that inactivates incretin hormones. Inhibition of DPP-4 result in an increase in the levels of hormones [e.g. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotrophic polypeptide)] which regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic β-cells and decreasing glucagon secretion from the pancreatic α-cells, leading to reduced hepatic glucose production.
Absorption: Absorbed from the gastrointestinal tract. Bioavailability: Approx 100%. Time to peak plasma concentration: Approx 1-2 hours.
Distribution: Volume of distribution: 417 L. Plasma protein binding: 20%.
Metabolism: Minimally metabolised in the liver by CYP2D6 and CYP34A to active and inactive metabolites.
Excretion: Mainly via urine (76%, 60-71% as unchanged drug); faeces (13%). Terminal elimination half-life: Approx 21 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Alogliptin, CID=11450633, (accessed on Jan. 20, 2020)

Store at 25°C.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH04 - alogliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Anon. Alogliptin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 02/02/2018.

Buckingham R (ed). Alogliptin Benzoate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 02/02/2018.

Joint Formulary Committee. Alogliptin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 02/02/2018.

McEvoy GK, Snow EK, Miller J et al (eds). Alogliptin Benzoate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 02/02/2018.

Nesina Tab, Film-Coated (Takeda Pharmaceuticals America, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 02/02/2018.

Disclaimer: This information is independently developed by MIMS based on Alogliptin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in